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TheranosticThe discovery and development of biomarkers for ﬁbrotic diseases have potential utility in clinical decision-
making as well as in pharmaceutical research and development. This review describes strategies for identify-
ing diagnostic, prognostic and theranostic biomarkers. A range of technologies and platforms for biomarker
discovery are highlighted, including several with speciﬁc relevance for ﬁbrosis. Some challenges speciﬁc to
ﬁbrotic diseases are outlined including; benchmarking biomarkers against imperfect clinical measures of
ﬁbrosis, the complexity resulting from diverse aetiologies and target organs, and the availability of samples
(including biopsy) from well-characterised patients with ﬁbrotic disease. To overcome these challenges
collaboration amongst clinical specialities as well as between academia and industry is essential. This article
is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The potential value of biomarkers in revolutionizing both the way
we deﬁne and monitor diseases, and the way we target and assess the
impact of therapies, is well recognised. This potential undoubtedly
applies to ﬁbrotic disease where major clinical outcomes may take
years, if not decades, to manifest. This need to identify short term
readouts of progression and prognosis has driven increasing effort in
the ﬁeld of biomarker discovery for ﬁbrosis.
It is worth recognizing at the outset that despite their potential
impact, only a small number of biomarkers are currently used in rou-
tine clinical practice, and few have gained broad acceptance, even
as tools in experimental settings. This begs a number of questions:
do we have the right expectations for what biomarkers offer both
clinical practice and drug discovery? Are we identifying biomarkers
in the right way? Are we applying existing biomarkers correctly to
ensure they are most informative?
In this reviewwewill draw upon some speciﬁc examples to explore
how we might identify and utilise biomarkers for the study and treat-
ment ofﬁbrotic diseases by setting appropriate expectations and deﬁni-
tions of ‘validation’, and by the application of newer biotechnologies
and statistical methodologies. In the authors' view, the prospects fors: Translation of basic research
Marshall),
@gsk.com (P.T. Lukey).
rights reserved.meaningful biomarker discovery in ﬁbrotic disease are good. But al-
though progress is being made in some areas, there remains much
work to be done.
2. Concepts and pitfalls
There are some general principles that can help to deﬁne the
quality of a biomarker—its accuracy, for example; these apply to
any new test or assay under evaluation and are not covered here.
However, what represents a valuable, valid biomarker will very
much depend on the question it is trying to answer. Similarly, the
standards against which we assess new markers, themselves, may
be imperfect, which can lead to a vicious loop in the validation pro-
cess, and a not uncommon scenario in the early stages of biomarker
discovery. This should not deter us from moving forward, but a de-
gree of caution will be required as we look to deﬁne new gold
standards.
2.1. Biomarker types: what question are we trying to address?
Biomarkers can be measurements of physiological and pathological
processes, or drug effect. In practice, biomarker discovery has generally
aimed to answer one of three key questions: can they distinguish
disease from health or other similar diseases (a diagnostic); can they
predict mortality, exacerbation, disease progression (a prognostic); or
can they predict a response to therapy (a theranostic).
Candidate biomarkers are often derived, in the ﬁrst instance, from
preclinical in vitro and in vivo models that try to mimic relevant pro-
cesses e.g. bleomycin-induced pulmonary ﬁbrosis in rodents [4] or
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(e.g. measurement of Transforming Growth factor (TGF)beta and
its downstream effects [12,33], or extracellular matrix components
(ECM)[11,64]) have also been used. Biomarkers identiﬁed in this way
will therefore come with the same pros and cons inherent in such
non-human systems. However if human cells and tissues can be used,
and open-platform techniques (e.g. transcriptomics, metabolomics, pro-
teomics, etc.[50]) applied with no a priori assumption of a biomarker's
value, these more controlled settings can be valuable. Ultimately, of
course, it is in the clinical setting that a biomarker has to prove its
worth, and some common approaches are outlined below, with their
application to drug discovery summarised in Fig. 1:
Diagnostics: Biobanked samples from patient cohortsmay be used to
compare putative biomarkers in ﬁbrotic disease vs. non-ﬁbrotic dis-
ease or healthy controls. Retrospective analysis can be performed on
these stored sampleswhichmay identify candidate biomarkers. Any
candidate biomarker should then be conﬁrmed in patients recruited
prospectively. Recruitment bias can be a problem depending on
the method for subject identiﬁcation, e.g. enrollment criteria
and this is at least one reason why markers may fail to replicate
across studies.
Prognostics: For this purpose, a baseline sample (e.g. blood, urine,
bronchoalveolar lavage) can be correlated with clinical outcomes
such as disease progression, exacerbations, and mortality. OneFig. 1. Discovery and development of drugs and biomarkers. The drug discovery and development p
launch of the newmedicine. Biomarker discovery and development activities (blue chevrons) can
into two types. The ﬁrst type of biomarker (Disease Biomarkers) involves the discovery and deve
markers may be discovered by applying open platform technologies (‘omics’) to tissues and cells
The large amounts of complex information derived from these experiments may be analysed and i
those markers with the potential to diagnose disease, predict patient outcomes and to stratify
decision-making and then further developed through to surrogate markers thatmay be approved fo
the discovery and development of markers that relate to the medicine being developed and these c
(pharmacodynamic effects). These biomarkers may be developed in order to ensure that the mediimportant issue with this approach is that ‘baseline’ represents a
point in the disease process when the patient presents at the clinic
but the underlying disease may have been present for years if
not decades before diagnosis. Therefore, there is little consistency
between patients as to what ‘baseline’ represents and this can
complicate any relationship with outcomes. It may also be help-
ful to measure change in a biomarker over a short period of time
(1–3 months) in relation to a longer-term outcome at, say, one
year, which still offers a considerable time advantage. Deciding
whether markers are best assessed statically or dynamically
may be difﬁcult to predict, and erring on making assessments
at multiple time points is probably ideal, in the ﬁrst instance.
Theranostics: Development of biomarkers that predict a response to
therapy have been somewhat neglected, as effective anti-ﬁbrotic
therapies have not been available and, therefore, there is no
‘gold-standard’ treatment. One obvious starting point is to look at
changes in prognostic markers in response to a therapeutic
intervention, the assumption being that an effective therapy that
induces a change in such biomarkers will be more likely to produce
longer-term clinical beneﬁt. One pitfall with this approach is that an
effective therapy may act via a biological mechanism that does not
directly impact the prognostic marker. In this context, having
markers that are as closely associated with core processes (i.e.
matrix production) likely to affect disease outcome, can reduce
this risk.ipeline (green chevrons) starts fromdrug target identiﬁcation through to approval and
be envisioned as occurring in parallel to the drug pipeline. Biomarkers can be divided
lopment of markers that relate to the patient and their disease processes. These bio-
derived from in vivo and in vitro models as well as from well-characterised patients.
nterpreted using computational biology and pathway analytical approaches to reveal
them for therapeutic interventions. Initially biomarkers may be used for internal
r use by regulatory bodies. The second type of biomarker (Drug Biomarkers) involves
an be focussed on the speciﬁc downstream events that occur after target engagement
cine is provided to those patients who will derive the most beneﬁt.
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A common issue encountered with disease biomarkers (be they
prognostic or diagnostic) is that current disease deﬁnitions may,
themselves, be based on imperfect clinical descriptors. In idiopathic
pulmonary ﬁbrosis, for example, wemight expect a biomarker related
to ﬁbroblast function to impact forced vital capacity (FVC). How real-
istic is this when FVC was not developed as a test to monitor ﬁbrotic
lung disease speciﬁcally and is likely to be impacted by factors not
directly related to the severity and progression of IPF [65]? Ideally,
going forward, new biomarkers will actually deﬁne disease pheno-
types more accurately, based on the activity of underlying patho-
mechanisms; but for now, this apparent paradox means we should,
at least, consider biomarkers as indicators of biological processes
rather than diseases. This also applies in the context of pharmacolog-
ical action. Drugs target pathways and processes, and it is at this level
we should look ﬁrst to understand pharmacodynamic (PD) action
using a biomarker. If this same marker then predicts an important
clinical outcome it falls into the subcategory of surrogate, and the ad-
ditional demands that requires [25,62]. But here we need to be careful
that it is reasonable to try to make this link. The most accurate PD
marker may not relate directly to the biology of interest, particularly
if the drug target has many downstream consequences (for example
a change in gene expression related to the inhibition of an upstream
kinase). Otherwise we may be asking something of the marker that
it cannot reasonably deliver. When there is a statistical relationship
but no biological hypothesis, we might assume the relationship still
holds on the grounds that we are simply ignorant of the relevance
of those pathways to the disease process, but caution is required
when identifying surrogates in this way.
Another important area is the concept of validation. The term im-
plies a single level of quality and utility all biomarkers must reach to
become “valid” [35]. But holding all biomarkers to such high stan-
dards will mean we may dismiss many that could be useful either
alone or in combination. Any biomarker measurement has a varying
degree of error and hence uncertainty that needs to be accounted
for when making decisions (clinical or strategic). As an example, the
early evaluation of a new drug is often a process of discharging the
clear risks associated with a novel molecular entity in what may be a
new disease indication. Does it have the right pharmacokinetic (PK)
properties, is it tolerated safely, does it engage the target mechanism
in the relevant tissue, and, of course, ultimately, is it efﬁcacious? Our
assessment of each of these often already depends on biomarkers and,
in some instances, such as PK, we may feel more conﬁdent in assessing
the uncertainty in those measurements, and allowing for this when
deﬁning the probability the data are true. This is because the question
we are asking (is the drug present and in what concentration?) is
clear, and the assay (e.g. mass spectrometry) has been developed spe-
ciﬁcally for this purpose and has been tested rigorously with samples
generated in vitro and in vivo. Clearly there is a level of uncertainty
that would render a biomarker measurement worthless but often we
just need to deﬁne the uncertainty and of course try to account for it
in our study designs if possible.
Leading on from this, another important aspect of using biomarker
data successfully is establishing a priori how decisions will be made.
Study analysis plans or clinical management algorithms need to state
how much weight a given marker carries in deciding, say, whether a
compound progresses, and how it should progress, orwhether a patient
receives a certain prognosis or therapy. In the context of drug discovery,
particularly when viewed as an iterative process of risk discharge, bio-
markers that have not reached the point of validation that would, say,
allow them to become regulator approved diagnostics, can still have
enormous value. Many now speak of ‘qualiﬁcation’ as a better term to
deﬁne a level of conﬁdence in the behaviour of a given biomarker that
allows it to be part of a decision making process. What determines the
weight given to such a biomarker signal will depend on the questionbeing asked and the biological context. It also speaks to the risk in
the accuracy of the decision being made that is deemed acceptable
in any given scenario. These numerous uncertainties may drive us
more towards the use of multiple biomarker readouts in a ‘weight
of evidence’ approach.
Replication in prospective patient cohorts is also key to testing the
robustness of a biomarker. A high degree of variability between indi-
vidual clinical centres or between cohorts is of concern if no obvious
explanation can be identiﬁed. A lack of replication, which is common
in biomarker studies has a number of sources. Recruitment bias, dif-
ferences in the interpretation of diagnostic tests and in sample man-
agement can introduce variation. Differing statistical methodologies
also contribute and are discussed later. One particularly thorny issue
is that of ‘power’. While it is certainly true that larger, multi-center,
cohorts can reduce the likelihood of observations being made by
chance, it may be easier to reduce confounders and improve signal to
noise in smaller studies where very detailed phenotypic information
relevant to the question being addressed is available. Both approaches
can be valuable, although only some makers will ultimately hold up in
all instances.
2.3. Prospects in ﬁbrotic disease
The availability of gold standards for diagnosis and prognosis,
against which new markers can be assessed, is an important issue.
For example, an unknown etiology could represent a signiﬁcant chal-
lenge for ﬁnding biomarkers in IPF. Yet, this very fact has promoted
the use of radiologic and pathologic criteria, which might be more
objective and hence a better ‘anchor’ for the identiﬁcation and quali-
ﬁcation of new biomarkers. Hepatitis C, by contrast, has a well deﬁned
etiology, although even there, as with all diagnostic tests there is
a false positive and negative rate. As previously stated, biomarkers
themselves are likely to contribute to improved diagnostic criteria
going forward, and hence should not always be accepted or dismissed
purely on the basis of current methodologies for making those diag-
noses, particularly if they are biological plausible.
Another aspect of the ﬁbroproliferative process that might lend
itself to biomarker discovery is the dynamic nature of matrix turn-
over. Increasingly from animal models, and latterly in human studies,
ﬁbrosis is revealed as a dynamic process. Collagen synthesis is highly
regulated, with multiple intracellular and extracellular steps resulting
in modiﬁcation, or degradation that will generate potential biomarker
signals [29,53,66]. How we might capitalise on these aspects of the
ﬁbrotic process is discussed later on.
With the obvious exceptions like skin and the eye, ﬁbrotic disease
most commonly affects internal organs, and variable tissue availability
may hamper biomarker identiﬁcation and use. Markers that are more
‘proximal’ to disease mechanisms (i.e. derived from the key disease
cells/proteins) are likely to be more robust, hence access to tissues is
important in identifying and validating new markers that can subse-
quently be assessed in other, more accessible compartments. With
biopsies becoming harder to justify clinically, it is important the ﬁbro-
sis community maximises the use of available tissue. In the short term
it may be justiﬁable to use biopsies to help target new therapies, par-
ticularly if these treatments have signiﬁcant side effects, but non-
invasive, diagnostics and theranostics must be the ultimate goal.
To that point, the vascularity of the lungs, liver and kidneys,
coupled with the magnitude and diffuse nature of ﬁbrotic disease in
those organs suggests such non-invasive markers can, and should
be, identiﬁable. Urine is an obvious compartment for ﬁnding markers
of renal ﬁbrosis [38] but likely provides only a certain sample of the
available biomarker ‘space’ that may be more or less relevant to the
question being addressed. Hence, examining markers in multiple
compartments may be required.
Finally, the dynamic nature of ﬁbroproliferation, coupled with difﬁ-
culties of tissue access make imaging an attractive prospect. However,
Liver Fibrosis 123 48.24
Pulmonary Fibrosis 62 24.31
Cardiovascular Fibrosis 32 12.55
Renal Fibrosis 19 7.45
Skin Fibrosis 9 3.53
Ophthalmic Fibrosis 5 1.96
GI Fibrosis 3 1.18










Fig. 2. Non-intervention, observational clinical studies of ﬁbrotic diseases. Clinicaltrials.gov
contains 256 studies that are of potential interest for biomarker discovery in ﬁbrotic
diseases. These include ongoing and completed studies from a range of centres worldwide.
Studies on liver ﬁbrosis constitute 48.44%, pulmonary ﬁbrosis 24.22%, cardiovascular ﬁbro-
sis 12.5%, renal ﬁbrosis 7.42%, skin ﬁbrosis 3.5 % and the remaining 3.9% is made up of GI,
ophthalmic and systemic ﬁbrotic conditions.
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ﬁbrosis imaging methodologies are available. Functional imaging with
Positron emission tomography (PET) is a particularly exciting prospect
[26]. One problem is that the liver and kidney are important elimination
routes for PET ligands and tend to demonstrate high background
signals. This might be circumvented by novel protocols and analytical
methodologies that examine the dynamic nature of such signals and
better distinguish signal from noise [67].
3. What have we learnt so far in ﬁbrosis?
Clinical samples are most valuable when collected prospectively
from large numbers of patients with detailed phenotypic information
regarding diagnostic tests, severity, progression, co-morbidities and
ultimately mortality. In order to assess the potential availability of
such samples, we conducted a search of the clinicaltrials.gov data-
base. Using the search word ‘ﬁbrosis’ and including only observation-
al studies, a total of 455 clinical studies were identiﬁed. Removing
inappropriate studies (e.g. cystic ﬁbrosis, intervention studies incor-
rectly labeled as being observational, and other irrelevant studies)
256 studies remain that may be useful for the discovery and develop-
ment of biomarkers for ﬁbrotic diseases. These are summarised in
Fig. 2 (see supplemental information for a complete listing).
Almost half of the studies identiﬁed were in liver ﬁbrosis covering
a wide spectrum of chronic liver diseases including, but not limited
to: alcoholic liver disease, non-alcoholic fatty liver, viral hepatitis,
and transplant-rejection. Blood and biopsy tissue were the most com-
mon sample type, subjected to both open-platform and mechanisti-
cally focused methodologies, as well as a number of imaging
approaches. Given the predominance of activity in this disease area
we have reviewed a few of the most high proﬁle approaches:
The Fibrotestwas originally described in a cohort of patients with
hepatitis C (training set of 205 patients and validation set of 134
patients), undergoing liver biopsy to detect ﬁbrosis [34]. At the
same time as the biopsy, a serum sample was taken and 11 se-
lected markers were measured. These markers were chosen
based on the known processes of liver damage and ﬁbrosis
(alpha2-macroglobulin, alpha2-globulin, gamma-globulin, apoli-
poprotein A, gamma-glutamyltransferase, total bilirubin, IL-10,TGFbeta, hepatocyte growth factor, aspartate aminotransferase
and alanine aminotransferase). The correlation between the his-
tological ﬁbrosis score and these markers, analysed singly and in
groups, was strongest for 6 markers measured together: alpha2-
macroglobulin, alpha2-globulin, gamma-globulin, apolipopro-
tein A, gamma-glutamyltransferase, total bilirubin. The Fibrotest
was therefore developed using a small set of markers selected on
the basis of their known involvement in the biology of liver damage
using histology scores of ﬁbrosis as the gold standard comparator.
This is a valid approach but it has limitations as only a very small num-
ber ofmarkers was analysed and it is possible that othermarkersmay
have been equally if not more predictive of the histology score. Fur-
thermore, using the histology score of a liver biopsy is, in itself, a lim-
ited measure of the extent of ﬁbrosis in the whole organ [8]. This is a
good example of how an imperfect gold standard can hamper bio-
marker discovery, with sampling error, use of a limited categorical
scale and signiﬁcant variability in scoring between observers all con-
tributing to inaccuracy. The need here is for more sensitive mechanis-
tic markers to be developed in human liver tissue, against which new
markers can be assessed.
The ELF (enhanced liver ﬁbrosis)measures serummarkers of liverﬁbro-
sis and then an algorithm combining age, hyaluronic acid, amino-
terminal propeptide of type III collagen, and tissue inhibitor of matrix
metalloproteinase-1 is applied [59]. The algorithm detects ﬁbrosis
(sensitivity, 90%) and also the absence of ﬁbrosis. However, the
algorithm varies, depending on which scoring system is used to
determine the extent of histologically observed ﬁbrosis (Scheuer
D=− .014·LN(age)+.616·LN(HA)+.586·LN(PIIINP)+.472·
LN(TIMP-1)−6.38; Ishak D=− .08·LN(age)+.608·LN(HA)+
.601·LN(PIIINP)+.511·LN(TIMP-1)−6.26). Some of the caveats
that apply to the Fibrotest, also apply to the ELF test: small number
of markers investigated and the histology scores are somewhat
ﬂawed.
The Fibroscan® is an ultrasound-based, non-invasive transient
elastography technique that is used in some cases as an alternative
to liver biopsy (reviewed in [68]). Low-frequency vibrations are
transmitted from the right intercostal space creating an elastic
shear wave that propagates into the liver. A pulse-echo ultrasound
acquisition is used to detect the velocity of wave propagation. This
velocity is proportional to tissue stiffness, with faster wave pro-
gression occurring through stiffer material. Measurement of liver
stiffness is performed and measured in kilopascals. This measure-
ment has been shown to correlate with the histological extent of
ﬁbrosis using biopsy material. For patients with stage IV ﬁbrosis
(cirrhosis), the pooled estimates for sensitivity were 87% (95%
conﬁdence interval [CI], 84%–90%), speciﬁcity 91% (95% CI, 89%–
92%), positive likelihood ratio 11.7 (95% CI, 7.9–17.1), and nega-
tive likelihood ratio 0.14 (95% CI, 0.10–0.20). The technique was
less sensitive and speciﬁc for less severe forms of liver ﬁbrosis. It
is concluded that ultrasound-based transient elastography may be
clinically useful for detecting cirrhosis [68]. However, Fibroscan® is
not always possible in all patients. The only factor associated with
failure was body mass index (BMI) greater than 28 (odds ratio,
10.0; 95% conﬁdence interval, 5.7–17.9, P=0.001) [19]. The utility
of Fibroscan® will vary depending on the BMI of the population to
be studied. It is also inﬂuenced by other non-ﬁbrotic processes that
affect tissue stiffness, such as fat and edema.
Some studies have compared these tests prospectively. In one re-
cent example, 175 patients undergoing liver biopsy to diagnose
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blood sample was taken on the same day as the biopsy and ultra-
sound investigations were conducted within 15 days of biopsy. This
enabled the investigators to evaluate the diagnostic accuracy of ELF
[59], Fibroscan® [22] and acoustic radiation force impulse imaging
(ARFI) [20] individually and in combination. Fibroscan® was unsuc-
cessful in 11% of subjects but ARFI was able to provide information
for all individuals. ARFI was as effective as either Fibroscan® or ELF
in predicting ﬁbrosis or cirrhosis. However, there was a trend for
the ultrasonographic markers to outperform the serological assess-
ment. It appears that the combination of ARFI or FibroScan® with
ELF may help better identify patients with or without signiﬁcant ﬁ-
brosis or cirrhosis [13]. This study has the advantage of being pro-
spective, of recruiting relatively large patient numbers and of
evaluating training and validation datasets. However, there is still
the inherent limitation of the use of biopsy histology as the gold stan-
dard diagnostic criterion for liver ﬁbrosis [8]. Although the study was
not intended to be longitudinal, follow-up samples and scans would
allow assessment of the ability of these biomarkers to track disease
progression.
Repeated assessments of Fibrotest and Fibroscan® have been used
in a number of other studies including one of those identiﬁed in clinical
trails.gov (NCT01306110) [15]. In this study, 277 patients hospitalised
due to complications of their diabetes were screened prospectively for
nonalcoholic fatty liver disease. Consecutive patients with type 1 or 2
diabetes had both clinical and biological parameters of liver ﬁbrosis
evaluated. Severe liver ﬁbrosis was predicted in 15.5% (FibroTest
>0.59 or FibroScan® >8.7 kPa) without any reference to biopsy. This
study claims to show an elevated prevalence of severe ﬁbrosis in
hospitalised diabetic patients, especially patients aged 50 years or
older with type 2 diabetes, or with a past history of foot ulcer [15]. It
is evident from this type of study that non-invasive tests are being relied
upon in some settings to predict liver ﬁbrosis in at-risk patients. The au-
thors conclude that biopsy studies are required in order to conﬁrm their
estimates of the prevalence of liver ﬁbrosis.
All three of these tests appear better able to detect the presence or
absence of more severe ﬁbrosis rather than intermediate degrees of
ﬁbrosis. They may also have greater utility in speciﬁc settings, for ex-
ample in monitoring the effect of certain drug classes, or helping to
phenotype patients for entry in clinical trials, rather than as prognos-
tic indicators.
In lung ﬁbrosis, Kaminski and colleagues at the University of Pitts-
burgh have conducted a number of thoughtful studies that illustrate
several key points in biomarker discovery and development and
have made a major contribution to the ﬁeld. Initial studies from this
group used gene expression proﬁling of animal models [36,75] and
primary human cells stimulated in vitro with relevant growth factors
[10] to model a ﬁbrotic signature. This was then translated into gene
expression proﬁles in the lungs and blood of patients with ﬁbrotic
diseases in order to enhance diagnosis [40], to identify complications
[73] and co-morbidities [56], and to predict outcome [31]. In addition,
a proteomic approach was also taken to identify surrogate markers
[57]. These studies have been greatly facilitated by the development
of a state registry of IPF patients [43] as well as a patient-initiated
warm autopsy program that allows access to signiﬁcant quantities
of ﬁbrotic lung tissue [44]. Further, work needs to be undertaken by
other investigators in different patient cohorts in order to determine
the utility of these potential biomarkers. This work emphasises the
long-term investment and effort required to discover and develop
relevant biomarkers for ﬁbrosis and the value of human tissue.
A number of prospective cohorts in IPF are being followed. For ex-
ample in the PROFILE study (NCT01110694 andNCT01134822) patients
with IPF will be followed up for at least 6 months, but potentially for 3
or more years, with serial samples taken for biomarker discovery using
open and closed platforms, together with detailed phenotypic informa-
tion. Importantly, the cohort can be divided into training and validationsets, with hypotheses developed in the ﬁrst set, subsequently tested a
priori in the second. This study is disadvantaged by the paucity of
matching lung biopsy material available in IPF.
3.1. Examples from other disease areas outside ﬁbrosis
As more and more studies are conducted, our attentions will inev-
itably turn to howwe use these datasets to reach a consistent view on
the utility of the putative markers identiﬁed. In this regard, it is per-
haps interesting to consider how the rheumatology ﬁeld has dealt
with reaching a consensus and adopting novel endpoints to facilitate
both interventional and observational clinical studies. In 1992 an in-
ternational body, ‘OMERACT’, was established. This is an informally
organised network aimed at improving outcome measurement in
rheumatology [70]. It is chaired by an executive committee, and
holds consensus conferences in a 2-yearly cycle that circles the globe.
Attendees are limited to experts in the ﬁeld (e.g. scientists, physicians,
statisticians and nurses), patients and representatives from industry
and regulatory bodies. In practice, the organizing committee polls
experts and opinion leaders to generate interest in the topic at hand.
These individuals then form a committee to guide the subsequent pro-
cess. The process is data-driven and iterative, and has evolved over
the past 14 years. One or more of the executive committee members
continue to be actively involved in each task force [70]. There may be
some value in considering a similarmodel for adopting novel endpoints
of ﬁbrotic disease into accepted practice. Such an initiative could oper-
ate both within disease areas, but also across ﬁbrotic diseases.
In the respiratory ﬁeld, biomarker discovery has been facilitated in
chronic obstructive pulmonary disease (COPD) by the ECLIPSE study
(Evaluation of COPD Longitudinally to Identify Predictive Surrogate
Endpoints). ECLIPSE is a non-interventional, observational, multicentre,
three-year study in more than 1800 people with COPD (http://www.
eclipse-copd.com/). The availability of this large biobank of patient
samples and accompanying clinical information has generated a wealth
of new insights into this disease. Investigators have been able to identify
promising biomarkers that distinguish COPD from controls [17]; that
correlate with clinical outcomes [9,63]; and that identify subsets of
patients [71]. It is likely that additional studies will be performed on
this cohort to discover and develop more biomarkers that will facilitate
clinical management of these patients as well as drug discovery.
The ﬁeld of oncology has also been particularly successful in devel-
oping biomarkers that facilitate diagnosis, prognosis and predicting re-
sponse to therapy. These have been reviewed extensively elsewhere
[2,74], but it is worth considering the use of PET imaging and its possi-
ble applications to the ﬁeld of ﬁbrosis. A positron-emitting radionuclide
tracer linked to a biologically active molecule is injected into the patient
and three-dimensional images of tracer concentration within the body
are then constructed by computer analysis. In order to identify the
structures within the body that are detected by the tracer, a CT scan is
performed at the same time. [18F]-ﬂuorodeoxyglucose (FDG)-PET/CT
has been used successfully in oncology to detect tumours and to mon-
itor treatment responses (see reviews [5,14,32,69]). Cells that are rapid-
ly metabolising glucose will take up the tracer and become visible to
the scanner and can then be mapped to particular organs visualised
by CT. Recently, an [18F]-FDG-PET signal has been detected in the
lungs of patients with pulmonary ﬁbrosis which localises to areas of
honeycombing and ground glass opaciﬁcation [26]. The nature of this
signal is not clear, but might be due to inﬁltrating neutrophils, alveolar
macrophages, proliferating myoﬁbroblasts, hyperplastic epithelium,
bacterial colonisation, or a combination of these; however, it raises
the question whether this technology could be developed for use in
ﬁbrotic diseases similarly to its use in oncology. Novel tracers that
probe other biological functions (such as apoptosis, hypoxia, angio-
genesis, proliferation and protein synthesis) may also be useful for
development in ﬁbrotic diseases. There are limitations to the general
applicability of this technology (cost, technical complexity, radiation
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development to illustrate effects of novel therapies on relevant bio-
logical processes without the need for invasive biopsies.
These are just some approaches to biomarker discovery and de-
velopment. Given the likelihood that there are common processes
in the development of ﬁbrosis in different tissues, there should be
great opportunities for synergy, collaboration and learning across
diseases. It would appear prudent to focus on the similarities be-
tween the ﬁbrotic diseases in order to maximise these opportunities.
There may be parallels with the oncology ﬁeld where the similarities
between tumour cells, independent of their origin, have allowed
more rapid adoption of biomarkers into clinical practice and drug de-
velopment, though of course disease and drug speciﬁc markers will
also be needed.
4. Platforms for biomarker identiﬁcation
In the search for soluble biomarkers of ﬁbrosis, the individual
technology platforms used will have a signiﬁcant bearing on the
chances of success. Each has its pros and cons and, again, a combina-
tion of approaches is likely to be required. Those of particularly value
in the context of ﬁbrotic diseases are reviewed.
4.1. Gene expression proﬁling
Generally, genomic platforms are either microarray or sequencing-
based, regardless of the biomaterial they quantify (RNA, DNA, or DNA
methylation) [48]. Advances in micro array technology have enabled
the quantitative measure of DNA/RNA levels for a range of genes in
disease and healthy samples simultaneously. Establishment of the
MicroArray Quality Control (MAQC) consortium has led to the develop-
ment of quality control standards, which include the development of
experimental and computational methods for dealing with variations
between laboratories [1]. Next generation sequencing (NGS), too, has
evolved rapidly to allow the parallel sequencing of DNA fragments
in ever-shorter time frames; this is known as deep sequencing and
delivers increased sensitivity and accuracy. These techniques have also
been extended to include RNA sequencing (RNA-Seq) which enables
detection of ﬁne structure in the transcriptome e.g. allele-speciﬁc
expression and splice junctions. This means that RNA-Seq can be used
to complement and extend the data obtained from microarrays [48].
RNA naturally lends itself to open platform biomarker discovery as
the speciﬁcity, sensitivity and ampliﬁcation potential of nucleic acid
hybridisation makes it very amenable to high throughput analysis.
Synthesis of de-novo reagents from nucleic acids is straightforward, so
access to the required reagents is never limited [6]. However, despite
advances in genomic technologies, linking these to a disease phenotype
is often not straightforward as these changes may not translate into
function.
One other potential drawback with genomic proﬁling in whole
blood is the relevance of changes in circulating cells to organ ﬁbrosis.
Ideally proﬁling of disease tissue would be undertaken but this is of
course limited by tissue availability. This doesn't mean blood proﬁling
cannot be successfully used, but caution needs to be applied as to
the plausibility of any changes observed in the context of the disease
under investigation.
While proteomics can potentially go one step closer to provid-
ing markers related to biological function, assessing proteins con-
centrations in clinical samples is more challenging, as these
molecules cannot be ampliﬁed. This means having to cope with
the inherently low levels of protein in many cases, and the issue
of distinguishing them from the background signals of physiologi-
cal proteins present in high abundance, such as albumin and
other transporter proteins in the blood compartment. Proteins
assays fall, broadly into three main categories: immunoassays,separation and detection (typically using mass spectrometry),
and more recently aptamers.
4.2. Immunoassays
The most commonly-used immunoassay types are sandwich
immunoassays with capture and detection antibodies (Enzyme-linked
Immunoassays (ELISAs) and related technologies), ﬂow cytometry,
western blots and immunohistochemistry (IHC) [6]. There are a limited
number of antibodies available and developing these reagents can be
very time consuming. Polyclonal antibodies are generally the easiest
to produce, but they may recognise multiple epitopes of the antigen
and will have inherent batch-to-batch variability. Monoclonal anti-
bodies are much more difﬁcult to produce, but have the advantage
that they will only recognise one epitope of an antigen and once the
hybridoma is made, it is a constant and renewable source of the antigen
thatwill ensure all batches are identical. Traditionally, these assays have
been set up to look at a single protein and immunoassays using mono-
clonal antibodies are still often considered one of themost reliableways
to validate biomarkers, as they can be set up to look at proteins with
high sensitivity, typically down to the ng-pg/mL range.
In ﬁbrotic disease, proteins related to the extracellular matrix
(ECM) are likely to provide candidate biomarkers and are often co-
expressed with their cognate matrix metalloproteinases (MMPs),
several of which have been shown to be upregulated [54]. One prom-
ising biomarker approach capitalises on this, generating neo-epitope
assays that identify the speciﬁc products of ECM degradation. These
neo-epitopes are post-translational modiﬁcations of proteins gener-
ated by protease cleavage, citrullination, nitrosylation, glycosylation
or isomerisation. In liver ﬁbrosis, neo-epitope assays generated by
degrading collagens I, III, IV and VI with metalloproteinases have
been shown to be elevated in two rat models of ﬁbrosis [45]. The
potential of this approach is further demonstrated by data showing
upregulation of MMP9- generated fragment of collagen type III,
CO3-610 in the CCl4 rat model of liver ﬁbrosis. Levels rise steeply on
CCl4 treatment and correlate with the progression of ﬁbrosis [72].
A signiﬁcant relationship was also seen between marker levels and
hepatic portal pressure [61]. Data generated in human samples is
beginning to emerge demonstrating the consequences of excessive
and deranged ECM turnover in ﬁbrosis, which is believed, ultimately,
to drive organ failure [16,42,52].
4.3. Multiplexed immunoassays
Development of multi-analyte readouts using immunoassays is
not straightforward. Challenges include selection and immobilisation
of capture ligands, interference between antibodies, proteins and
assay diluents, calibration and compatibility of the assay limits of
detection [18]. Despite the challenges, multiplexed assays have been
developed using a range of technologies [39]. Multiplexes have the
advantage that a number of analytes can be investigated at the same
time using relatively small amounts of samples (when compared to
running multiple single assays), though typically 6–10 are measured.
The complexities of mixing reagents mean that multiplexes often
show batch-to-batch variation when reagents are changed, particularly
when polyclonal antibodies are used. In recent years, there have been
many publications investigating the reproducibility of commercially-
available multiplexes [18,21]. Such assay panels have now enabled the
screening of samples for up to a few hundred proteins and their utility
has been demonstrated for biomarker discovery purposes. For example,
a study in idiopathic pulmonary ﬁbrosis IPF used a multiplexed plat-
form to evaluate 92 proteins in plasma samples from 241 IPF patients;
75 of these proteins were detectable and 3 analytes from the panel
ICAM1, IL8, and VCAM1 were signiﬁcantly associated with mortality
and/or disease progression [58]. Multiplexed immunoassays, in a clini-
cal setting for diagnostic and prognostic use, have been hindered by
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view highlights that for multiplexed assays to be broadly applied,
there must be the establishment of globally accepted calibration stan-
dards, performance criteria and quality control [18].
4.4. Mass spectrometry
Mass spectrometry (MS) has been widely used to identify protein
and phosphoprotein biomarkers [7,46]. Fractionation, enrichment/
depletion and solubilisation protocols all have to be applied prior to
analysis by MS. When working with tissue samples, these need to
be solubilised to enable tryptic digestion and plasma samples have
to be depleted of the most abundant proteins, e.g. albumin, prior to
analysis. An excellent recent summary of MS-based proteinomics in
ﬁbrotic disorders [28] highlights that working with ﬁbrotic tissue is
especially challenging as ﬁbrotic tissues are harder to digest and
most of the biologically-important proteins are of lower abundance.
The most common method for detecting proteins involves isolating
a mixture and cleaving them enzymatically into peptides. The resul-
tant complex mixture is then fractionated by chromatography and
analysed by tandem LCMS (MS/MS). One problem with current one
dimensional LC-MS/MS approaches is that they fall short of the dy-
namic ranges required to measure protein concentrations from high
mg/mL to pg/mL. In recent years there have beenmany developments
to improve the sensitivity of MS-based proteomics, which have been
extensively reviewed [3,7]. These include technological advances
to improve instrument sensitivity and mass accuracy and improving
sample preparation. Increased depth in proteome coverage can be
accomplished, for example, by fractionation at either the protein or
the peptide level, or both, reducing sample complexity.
Analysis of post-translational modiﬁcations (PTM) by mass spec-
trometry is not straightforward. Often, the PTM is labile and to
observe their presence at low levels requires enrichment. There are
two methods commonly used for this:
1- Enrichment of samples based on antibodies, e.g. selecting for tyrosine-
phosphorylated proteins with an anti-p-tyr antibody.
2- Relying on a physicochemical property of the protein, e.g. serine-
or threonine-phosphorylated proteins/peptides can be enriched
using immobilised metal oxide afﬁnity proteins.
Phenotypic proﬁling can also be carried out using targeted MS.
Viewed simply, this technique can be thought of as analogous to
a western blot using mass spectrometry. Unlike the open platform
LC-MS/MS processes, which are biased towards the most abundant
and easily observable proteins, it enables detection and quantiﬁcation
of pre-determined peptide ions. However, the process of setting up a
targeted MS question can be quite involved, as described in a recent
review [27].
Numerous approaches have been developed to enable relative
protein quantiﬁcation; these include 2D ﬂuorescence gel electropho-
resis (DIGE), isobaric tag for relative and absolute quantitation (iTAQ)
and stable isotope labelling with amino acids in cell culture [28].
Ultra-high resolution mass spectrometry is being used to measure
collagen levels using stable isotope-labelling techniques [30]. Despite
collagen being a key component of ﬁbrotic disease, the essential role
it plays throughout the body means that changes in levels associated
with disease may be difﬁcult to distinguish from physiological back-
ground. Labelling proteins using D2O either in vivo or in vitro enables
the dynamics of collagen formation to be assessed. During the D2O
treatment period, deuterium is incorporated into newly-synthesised
proteins at low levels, which are detected by isotope ratio mass
spectrometry. The utility of this technique has been demonstrated
in rat and mouse models of liver ﬁbrosis. The animals were dosed
for up to 35 days with D2O, and deuterium incorporation into
collagen-bound amino acids alanine and hydroxyproline measured
by gas chromatography–mass spectrometry (GC–MS). Changes inisotopically-measured collagen synthesis correlated with, but were
more sensitive and reproducible than, standard histological staining
for ﬁbrosis using trichrome [23]. This is an exciting approach that
may dramatically increase the dynamic range for biomarker detec-
tion and observable change, whilst also offering the potential for
novel biomarker discovery both in vitro using human tissues and
cells, and in man.
4.5. Mulitplexed aptamer assays
Moving from antibodies to aptamers has been explored as a way
to expand the panels of proteins that can be investigated. Aptamers
are short, single-stranded oligonucleotides which can be endowed
with protein-like properties by adding functional groups that mimic
amino acid side chains. Slow off-rate modiﬁed aptamers (SOMAmers)
[41] have been developed with two basic properties; a unique shape
to bind a speciﬁc protein and a DNA sequence that permits recogni-
tion for detection purposes. Levels of SOMAmers are measured by
quantitative DNA techniques which can be related to the concentra-
tion of protein. Custom generation of synthetic SOMAmers to protein
targets is generally more rapid and less costly than developing anti-
body reagents. The uniformity of the reagents also makes multi-
plexing more straightforward. Currently, panels exist for measuring
>1000 proteins from ~15 μL of blood or other tissue with good sen-
sitivity (low fmol to mmol) [41]. Data using aptamer technology to
assess the levels of multiple proteins have been appearing in the liter-
ature for a couple of years now [24]. A recent example looked at pro-
tein expression levels in lung tumour tissue and identiﬁed 36 proteins
that consistently differ between both the tumour and adjacent tissue
and tumor and distant tissue [49]. This relatively new technology is
still to be evaluated in identifying biomarkers for ﬁbrotic disease.
5. Statistical approaches
What is clear from a review of the available platforms is that vast
amounts of data can be generated, all of which needs to be analysed
in a coherent and statistically robust way to ensure the accuracy of
any signals observed is as high as possible. For example, metabolomics
uses (commonly) MS[47,51] and/or 1H NMR[55] to characterise the
presence and ﬂux of metabolites, of which there are estimated to
be thousands in humans. Thus high-throughput proﬁling technolo-
gies present a new challenge: extracting meaning from a long list
of differentially-expressed genes, proteins or metabolites. Especially,
as making multiple measurements increases the chances of false
positive results.
Pathway analysis is often the ﬁrst choice for improving the quality
of data mining of differentially-expressed genes and proteins, and
has been reviewed recently [37]. This is based on the principle that
changes in multiple genes within a pathway, suggest co-ordinate
regulation, and are deemed more likely to be relevant in impacting
disease pathogenesis. This makes sense, as transcriptional regulation
in response to individual growth factors and their downstream sig-
nalling pathway involve numerous, co-ordinated changes in expres-
sion. This of course relies on a good pre-existing knowledge of the
biological pathways and may not be good at detecting hitherto un-
known pathways.
Other approaches to analysing data include multivariate analysis
techniques such as principal component analysis or independent
component analysis. This allows whole datasets to be mined to iden-
tify markers that segregate as a group to discriminate between end-
points such as diagnosis, clinical outcome, or therapeutic effect. A
recent statistical review on developing biomarkers, highlights that
correcting for multiplicity can be a challenge as some of the markers
may relate to the same biology [35]. Interpretation of the data in light
of the known biological relationships is crucial for drawing robust
conclusions [35].
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The identiﬁcation of biomarkers to track ﬁbroproliferation needs
to be a major focus in the coming years. Chronic diseases in which
ﬁbrosis is a key determinant of outcome already represent a major
disease burden and, in many cases, their prevelance is increasing.
There is a high probability of identifying relevant markers in the
peripheral blood compartment because of the dynamic nature of
matrix processing, its inﬂuence on cellular function, and its wide-
spread involvement of well vascularised internal organs and tissues.
The application of speciﬁc technologies focused on these processes
(particularly those that assess dynamic changes in marker expression)
in longitudinal studies against a robust clinical phenotypewill be critical.
Ultimately this will require a strong collaboration between academics,
pharmaceutical and biotechnology companies and we might look at
the OMERACT and ECLIPSE examples as a good precedent for the way
forward. Just as important will be the implementation of high quality
bio-analytical methodologies. This is well demonstrated by approaches
to genomic array data, where the MAQC consortium has been vital to
moving the technology forward in biomarker discovery.
Overall, we should be optimistic that new markers for ﬁbrosis
can be identiﬁed, but we should not necessarily expect one biomarker
to do all the things we need. Instead, we must match the biomarker
to the question being asked, and expect that more sophisticated
decision-making models will be required that allow us to determine
how, who and when to treat as accurately as possible.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.01.018.
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